AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Shinsan M. Su, Jeremy Travins et al.|Cancer Discovery|2017Cited by 457
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor EfficacyPeter S. Dragovich, Xiaoyu Zhu, Emel Adaligil et al.|Journal of Medicinal Chemistry|2021Cited by 168